CES 2021 MedFluid Develops First-In-Class Microfluidic Platform for Rapid Detection and Screening of Disease Diagnosis
Share this article Share this article TAIPEI, Taiwan, Jan. 17, 2021 /PRNewswire/ -- Health and Biotech company MedFluid has developed the fastest, first-in-class antimicrobial susceptibility test that will aid in providing precise medical prescriptions to improve the health and well-being of patients. MedFluid Founder and Head of Microfluidics R&D Bon Lee noted that, according to the World Health Organization (WHO), antimicrobial resistance was one of the ten threats to global health in 2019. "...
A Widely Recognized Company Center Innovation Program Innovation Startups Program Rapid Detection Personalized Antibiotic Screening Platform Personalized Antibiotics Screening
Source: prnewswire.com